Protection against experimental nervous system autoimmune diseases by a human immunodeficiency virus-1 Tat peptide-based polyvalent vaccine.
The human immunodeficiency virus-1 (HIV-1) Tat peptide is taken up by a variety of cells in vitro and in vivo (Anderson et al.: Biochem Biophys Res Commun 194:876-884, 1993; Fawell et al.: Proc Natl Acad Sci USA 91:664-668, 1994; Chen et al.: Anal Biochem 227:168-175, 1995). We have used Tat37-72, the fragment containing a domain binding to alpha v beta 5 integrin (Vogel et al.: J Cell Biol 121:461-468, 1993), to deliver a fusion protein of three pathogenic rat T-cell epitopes, MBP68-84, P2,53-78, and IRBP1169-1191 systemically and via mucoepithelial surfaces. This recombinant polyvalent vaccine peptide, toolbox101, is-depending on the route of administration-specifically immunosuppressive and can be used to vaccinate against experimental autoimmune encephalomyelitis, neuritis, and uveoretinitis and is, in addition, of therapeutic value.